Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.
Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

Read More

Overview

Feature Articles

Latest Prostate Cancer News and Research

EZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancer

EZH2 enzyme drives aggressive tumor growth in treatment-resistant prostate cancer

How different types of bread impact cancer risk

How different types of bread impact cancer risk

Study identifies DNA collisions driving genetic changes in cancer

Study identifies DNA collisions driving genetic changes in cancer

Obesity crisis in the U.S. expected to worsen by 2050

Obesity crisis in the U.S. expected to worsen by 2050

MRI-guided SBRT reduces side effects in prostate cancer treatment

MRI-guided SBRT reduces side effects in prostate cancer treatment

Study uncovers why white button mushrooms may help prevent prostate cancer progression

Study uncovers why white button mushrooms may help prevent prostate cancer progression

New treatment combination improves outcomes for small cell bladder and prostate cancer patients

New treatment combination improves outcomes for small cell bladder and prostate cancer patients

Overtreatment of older men with prostate cancer raises concerns

Overtreatment of older men with prostate cancer raises concerns

Pesticide exposure linked to prostate cancer incidence and mortality

Pesticide exposure linked to prostate cancer incidence and mortality

Study highlights long-term risks of prostate cancer treatment

Study highlights long-term risks of prostate cancer treatment

Michigan study finds virtual care does not lead to wastage of healthcare resources

Michigan study finds virtual care does not lead to wastage of healthcare resources

New research explores how omega-3 and omega-6 fatty acids may impact cancer rates

New research explores how omega-3 and omega-6 fatty acids may impact cancer rates

AI-powered MRI predicts outcomes in prostate cancer

AI-powered MRI predicts outcomes in prostate cancer

22 pesticides found to be associated with prostate cancer incidence in the United States

22 pesticides found to be associated with prostate cancer incidence in the United States

Quitting smoking after cancer diagnosis can add years to patient lives

Quitting smoking after cancer diagnosis can add years to patient lives

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

Weill Cornell Medicine teams receive funding from Starr Cancer Consortium

AI model could help clinicians to understand prostate tumor's aggressiveness

AI model could help clinicians to understand prostate tumor's aggressiveness

Urine transcriptomics: A new frontier for non-invasive genitourinary disease detection

Urine transcriptomics: A new frontier for non-invasive genitourinary disease detection

Study identifies six cancer susceptibility genes

Study identifies six cancer susceptibility genes

Study uncovers six cancer susceptibility genes

Study uncovers six cancer susceptibility genes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.